More Articles Back to Article

Chinese regulators approve marketing authorization for Tagrisso

AstraZeneca's Tagrisso received a marketing authorization from the National Medical Products Administration in China. The drug was approved by Chinese regulators in 2017 to treat small-cell lung cancer. European Pharmaceutical Review (UK) (9/5)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!